Fig. 2

Cumulative incidence plot stratified by compliance with tumor board treatment recommendation for a genomic-low/intermediate-risk patients, and b genomic-high-risk patients. ADT androgen deprivation therapy, PSA prostate-specific antigen, RT radiotherapy